Australia's most trusted
source of pharma news
Tuesday, 28 July 2026
Posted 28 July 2026 AM
Johnson & Johnson has a drug that's taking off globally and replacing the revenue lost from its blockbuster Stelara going off patent but it's not seeing the same joy in Australia.
"Tremfya remains the fastest-growing advanced therapy in both Crohn's disease and ulcerative colitis, delivering exceptional overall sales growth of 71 per cent in the [second] quarter," J&J CEO, Joaquin Duato, told an earnings call.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.